Elaina Williamson
Family · Lake City, FLNPI 1053851451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Novo Nordisk at 28.5% of the total. Reporting peaked in 2021 at $1,105 and has fallen 90.2% since, to $108 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Merck$391
- Amgen$211
- Lilly USA, LLC$204
- Novartis$161
- Johnson & Johnson$157
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,739100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,739 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $99,301 |
| EliquisApixaban | 73 | $78,252 |
| OzempicSemaglutide | 53 | $76,229 |
| FarxigaDapagliflozin Propanediol | 50 | $49,209 |
| EntrestoSacubitril/Valsartan | 23 | $30,994 |
| JardianceEmpagliflozin | 26 | $29,983 |
| Repatha SureclickEvolocumab | 28 | $25,378 |
| RybelsusSemaglutide | 11 | $19,599 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $18,794 |
| VascepaIcosapent Ethyl | 15 | $10,678 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,780 |
| Repatha SyringeEvolocumab | 12 | $8,893 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,075 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $7,811 |
| Lagevrio (Eua)Molnupiravir | 11 | $6,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $156 | $116,89296 claims |
| Novo NordiskOzempic, Rybelsus | $1,066 | $95,82864 claims |
| PfizerEliquis | $128 | $78,25273 claims |
| AstraZenecaFarxiga | $129 | $49,20950 claims |
| NovartisEntresto | $161 | $30,99423 claims |
| Boehringer IngelheimJardiance | $15 | $29,98326 claims |
| MerckLagevrio (Eua) | $391 | $6,92611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Lake City
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.